We refer to the announcement dated 25 February 2022 on the Memorandum of Understanding entered into between Pharmaniaga Lifescience Sdn Bhd (“Company”) & BioNet-Asia Co. Ltd. (“BioNet”). We wish to announce the following progress:
- The Company had on 13 December 2022 entered into a Research Collaboration Agreement (“RCA”) with BioNet to collaborate and develop 6-in-1 combinational vaccine ("Hexavalent vaccine") using BioNet formulation to meet the specification as agreed by the parties.
- The formulation is scheduled to be ready by end of 2023, hence, will allow the Company to proceed with pre-clinical & clinical development, registration, manufacturing and expected to be commercialised in 2026.
- Hexavalent vaccine (containing acellular pertussis) is currently used in the Malaysia National Immunisation Program (NIP) and is fully imported. As part of the Company’s vaccine development and manufacturing plan, Pharmaniaga will aggressively develop Hexavalent vaccine in order to reduce import dependency and cost to the Government.
- The local market demand for the Hexavalent vaccine is estimated to be around RM200 million annually. Pharmaniaga look forward to supply the Hexavalent vaccine to the Ministry of Health, Malaysia and export to other parties worldwide. The demand for the regional market is expected to be around RM500-600 million annually.
- By having the first formulation for human vaccine it will strengthen the Company’s biopharmaceutical business footprint in the region and globally.
This announcement is dated 13 December 2022.